Saccharomyces boulardii protease inhibits Clostridium difficile toxin a and b-induced effects in human colonic mucosa

Castagliuolo, Ignazio; Valenick, Leyla; Riegler, Martin; LaMont, J. Thomas; Pothoulakis, Charalabos

doi:10.1016/s0016-5085(98)83862-6

Cited by 89 publications

(111 citation statements)

References 0 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…During the intestinal transit, S. boulardii interacts with resident microflora and intestinal mucosa. Moreover, experimental studies suggest that S. boulardii is protective against enteric pathogens, modulating the host immune response, decreasing inflammation and hydro electrolytic secretions, inhibiting bacterial toxin and enhancing trophic factors such as brush border membrane enzymes and nutrient transporters (7,8,10,14,37,53,40,44,47) .…”

Section: Discussionmentioning

confidence: 99%

Treatment of Diarrhea-Predominant Irritable Bowel Syndrome With Mesalazine and/or Saccharomyces Boulardii

Boiocchi

Almeida

Leite

et al. 2013

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Results -Compared to baseline, there were statistically significant reduction of symptom score after 30 th day therapy in all three groups: MG (P<0.0001); MSbG (P<0.0001) and in SbG (P = 0.003). There were statistically significant differences in the symptom score at 30 th day therapy of the MG, MSbG and SbG groups (P = 0.03). There were no statistical differences between MSbG and MG symptom score at 30th day therapy (P = 0.9). Conclusions -The use of mesalazine alone, Saccharomyces boulardii alone or combined treatment with mesalasine and Saccaromyces boulardii improved IBS-D symptoms. The improvement of the symptom score was greater with mesalazine alone or combined with Sb as compared with Sb treatment alone. These preliminary results suggest that mezalazine may be useful in treatment of IBS-d patients, and warrant further larger studies. HEADINGS -Irritable bowel syndrome. Diarrhea. Mesalamine. Saccharomyces boulardii.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of Diarrhea-Predominant Irritable Bowel Syndrome With Mesalazine and/or Saccharomyces Boulardii

Boiocchi

Almeida

Leite

et al. 2013

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…The use of probiotics in combination with antibiotic treatments has shown promise. Furthermore, some probiotics have additional mechanisms that specifically target C. difficile (Castagliuolo et al, 1996). The use of probiotics is safe for most patients, although rare complications have occurred in immunocompromised adults and children (Hennequin et al, 2000;Borrelio et al, 2003).…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have looked at the CDT-binding effectiveness of various polymers. Synsorb 90 is an oligosaccharide bound to an inert polymer matrix that acts as a 'decoy toxin receptor' and reduces fluid secretion in rat ileal loop models of CDAD (Heerze et al, 1994;Castagliuolo et al, 1996). However, no controlled trials testing the efficacy of Synsorb 90 on CDAD have been published to date.…”

Section: Adsorbentsmentioning

confidence: 99%

Alternative treatments for Clostridium difficile disease: what really works?

McFarland

2005

Journal of Medical Microbiology

141

View full text Add to dashboard Cite

Vancomycin and metronidazole have been used for treating Clostridium difficile-associated disease (CDAD) for the past 25 years, but approximately 20 % of patients develop recurrent disease. The increasing incidence of nosocomial outbreaks, cases of recurrent CDAD and other complications (toxic megacolon, ileus, sepsis) has fuelled the search for different types of treatments. As the understanding of the pathogenesis of this disease has matured, newer treatment strategies that take advantage of these mechanisms have been developed. This review will describe such treatments and examine the evidence for each strategy.

show abstract

“…Saccharomyces boulardii appears to be the most effective microorganism; however, LGG has also proven to be effective in children [68,69]. S. boulardii, for which there is a risk of hematogenous dissemination in immunocompromised patients, was effective in inhibiting the recurrence of episodes of Clostridium difficile infection [70]. Although not all studies have confirmed the effectiveness of probiotics treatment in the prevention of AAD, a 2009 review has shown that effectiveness is mainly related to the strain used [71]; the studies have also confirmed that there is sufficient clinical evidence to support the use of Lactobacillus rhamnosus GG and S. boulardii strains in the treatment of antibiotic-associated diarrhea [72].…”

Section: Antibiotic-associated Diarrheamentioning

confidence: 99%

Probiotics and health: An evidence-based review

Aureli

Capurso

Castellazzi

et al. 2011

Pharmacological Research

235

131

View full text Add to dashboard Cite

a b s t r a c tThe intestinal microbiota is an ecosystem formed by a variety of ecological niches, made of several bacterial species and a very large amount of strains. The microbiota is in close contact with the intestinal mucosa or epithelial interface which is, after the respiratory area, the largest surface of the body, occupying approximately 250-400 m 2 . The physiological activities of the microbiota are manifold and are just being unraveled. Based on the observations of the multiple roles played by the microbiota in health and disease, the notion of modifying it with appropriate formulations, i.e. probiotics, is being tested in several settings.This review summarizes the current knowledge on probiotics and discusses both limitations and acquired evidence to support their use in preventive and therapeutic medicine.

show abstract

Saccharomyces boulardii protease inhibits Clostridium difficile toxin a and b-induced effects in human colonic mucosa

Cited by 89 publications

References 0 publications

Treatment of Diarrhea-Predominant Irritable Bowel Syndrome With Mesalazine and/or Saccharomyces Boulardii

Treatment of Diarrhea-Predominant Irritable Bowel Syndrome With Mesalazine and/or Saccharomyces Boulardii

Alternative treatments for Clostridium difficile disease: what really works?

Probiotics and health: An evidence-based review

Contact Info

Product

Resources

About